2 news items
Key Takeaways From TScan Therapeutics Analyst Ratings
TCRX
13 May 24
(NASDAQ:TCRX), expressing a variety of opinions spanning from bullish to bearish.
Summarizing their recent assessments
Unveiling 4 Analyst Insights On TScan Therapeutics
TCRX
23 Apr 24
a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations
- Prev
- 1
- Next